Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $70 from $60 and keeps an Overweight rating on the shares following the Q3 report. The firm cites increased optimism for KT-621 for the target bump.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Reports Q3 2025 Financial Results
- Kymera Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
- Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges
- Kymera Therapeutics price target raised to $73 from $70 at Morgan Stanley
- Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release